SOVREMENNAYA PEDIATRIYA.2016.6(78):75-79; doi 10.15574/SP.2016.78.75 

Protection of HIV-infected children after vaccination against hepatitis B 

Volokha A., Raus I., Demchyshina I., Chernyshova L.

Shupyk National Medical Academy of Postgraduate Education

Kiev City AIDS Center

Virology/AIDS Department of Central Epidemiology Service, Kiev, Ukraine 

Background. Co-infection of HIV/hepatitis B is quite common in the world, over 10% of HIV-infected people have chronic hepatitis B. The most effective method of prophylaxis of hepatitis B in people with HIV infection is vaccination. Immune response to vaccination against hepatitis B and duration of post-vaccination immunity in patients with HIV infection may be insufficient. The aim of this study was to investigate the immune protection against hepatitis B in children with HIV.

Methods. Study of post-vaccination immunity against hepatitis B by determining the level of anti-Hbs antibodies was conducted in 59 HIV-infected children who are under the supervision of the Kiev City HIV/AIDS Center and control group of 10 children not infected with HIV. All children received vaccination against hepatitis B.

Results. The study found low coverage of vaccination against hepatitis B in children with HIV infection — 45.7%. HIV-infected children after vaccinations against hepatitis B had low levels of immune defense — only 22.0% of vaccinated children had protective levels of anti-Hbs antibodies. The study revealed that the early start of antiretroviral therapy and lack of immune deficiency at the time of vaccination are important predictors of the duration of the immune response after vaccination against hepatitis B.

Conclusion. Early initiation of ART and vaccination against hepatitis B after the start of ARV treatment can keep the duration of immunity against hepatitis B in children with HIV-infection. There is a need to control the post-vaccination immunity and booster doses of vaccine introduction in children who have received immunization against hepatitis B before the start of ART.

Key words: HIV-infection, сo-infection, children, hepatitis B, vaccination.

REFERENCES

1. Lao-araya M, Puthanakit T, Aurpibul L et al. 2007. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine. 25: 5324—29. https://doi.org/10.1016/j.vaccine.2007.05.006; PMid:17566615

2. Bailey H, Townsend C, Semenenko I, Malyuta R. 2013. Cortina-Borja M and Thorne C for the Ukraine European Collaborative Study Group in EuroCoord. Impact of expanded access to combination antiretroviral therapy in pregnancy: results from a cohort study in Ukraine. Bulletin of the World Health Organization. 91: 491—500. https://doi.org/10.2471/BLT.12.114405; PMid:23825876 PMCid:PMC3699794

3. Mayers C, Posfay-Barbe KM, Aebi C et al. 2009. Determinants of vaccine immunity in the cohort of human immunodeficiency virus-infected children living in Switzerland. Pediatr Infect Dis J. 28; 11: 996—1001. https://doi.org/10.1097/INF.0b013e3181a78348; PMid:19820427

4. Ni JD, Xiong YZ, Wang XJ, Xiu LC. 2013. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 24: 117. https://doi.org/10.1177/0956462412472309; PMid:23467291

5. Fernandes SJ, Slhessarenko N, Souto FJ. 2008. Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine. Vaccine. 26: 1032—37. https://doi.org/10.1016/j.vaccine.2007.12.020; PMid:18242796

6. Menson EN, Mellado MJ, Bamford A et al. 2012. Guidance on Vaccination of HIV-Infected Children in Europe. HIV Medicine. 13(6): 333—336. https://doi.org/10.1111/j.1468-1293.2011.00982.x; PMid:22296225

7. Bekondi C, Zanchi R, Seck A et al. 2015. HBV immunization and vaccine coverage among hospitalized children in Cameroon, Central African Republic and Senegal: a cross-sectional study. BMC Infectious Diseases. 15: 267. https://doi.org/10.1186/s12879-015-1000-2; PMid:26164361 PMCid:PMC4499446

8. Mutwa PR, Kimberly R, Boer KR et al. 2013. Hepatitis B Virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr Infect Dis J. 32: 246—251. PMid:22976050

9. Cagigi A, Cotugno N, Giaquinto C et al. 2012. Immune reconstitution and vaccination outcome in HIV-infected children. Human Vaccine and Immunotherapeutics. 8(12): 1784—1794. https://doi.org/10.4161/hv.21827; PMid:22906931 PMCid:PMC3656066

10. Abzug MJ, Warshaw M, Rosenblat HM et al. 2009. Immunogenicity and immunologic memory after hepatitis B Virus booster vaccination in HIV-infected children receiving highly active anti-retroviral therapy. The Journal of Infectious Diseases. 200: 935—46. https://doi.org/10.1086/605448; PMid:19663708 PMCid:PMC2814776

11. Kerneis S, Launay O, Turbelin C et al. 2014. Long-term immune responses to vaccination in HIV-Infected patients: a systematic review and meta-analysis. Clinical Infectious Diseases. 58(8): 1130—9. https://doi.org/10.1093/cid/cit937; PMid:24415637 PMCid:PMC4761378

12. Moss WJ, Sutcliff CG. 2010. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis. 10: 630—4. https://doi.org/10.1016/S1473-3099(10)70116-X

13. Nwolisa E, Mbanefo F, Ezeogu J, Amadi P. 2013. Prevalence of Hepatitis B co-infection amongst HIV infected children attending a care and treatment centre in Owerri, South-eastern Nigeria. Pan African Medical Journal. 14: 89. https://doi.org/10.11604/pamj.2013.14.89.1711; PMid:23646225 PMCid:PMC3641926

14. Siriaksorn S, Puthanakit T, Sirisanthana T et al. 2006. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine. 24: 3095—99. https://doi.org/10.1016/j.vaccine.2006.01.045; PMid:16488516

15. Sanchez Perez МР, Velasco Benitez СА, Lopez Lopez Р. 2015. Seroprotection for hepatitis B after three doses of vaccine in Colombian HIV patients under the age of 18. Rev Col Gastroenterol. 30(1): 55—61.

16. Sticchi L, Bruzzone B, Caligiuri P et al. 2015. Seroprevalence and vaccination coverage of vaccinepreventable diseases in perinatally HIV-1-infected patients. Human Vaccines & Immunotherapeutics. 11(1): 263—269. https://doi.org/10.4161/hv.36162; PMid:25483544 PMCid:PMC4514310